🇺🇸 FDA
Patent

US 8486989

Inhibitors of serine proteases, particularly HCV NS3-NS4A protease

granted A61KA61K31/407A61K38/00

Quick answer

US patent 8486989 (Inhibitors of serine proteases, particularly HCV NS3-NS4A protease) held by Vertex Pharmaceuticals Incorporated expires Mon Jul 11 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Jul 16 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 11 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
34
CPC classes
A61K, A61K31/407, A61K38/00, A61K45/06, A61P